Compass Therapeutics (CMPX) Preferred Stock Liabilities (2018 - 2020)

Compass Therapeutics (CMPX) has 3 years of Preferred Stock Liabilities data on file, last reported at $129.9 million in Q1 2020.

• For the quarter ending Q1 2020, Preferred Stock Liabilities changed 0.0% year-over-year to $129.9 million; the trailing twelve-month figure through Mar 2020 stood at $129.9 million (changed 0.0% YoY), and the FY2020 full-year result was $129.9 million, changed 0.0% from the prior year.
• Preferred Stock Liabilities steadied at $129.9 million in Q1 2020, from $129.9 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $129.9 million in Q4 2018 to a low of $129.9 million in Q4 2018.
• A 3-year average of $129.9 million and a median of $129.9 million in 2018 frame the typical range for Preferred Stock Liabilities.
• Peak annual rise in Preferred Stock Liabilities reached 0.0% in 2019, while the deepest fall reached 0.0% in 2019.
• Tracing CMPX's Preferred Stock Liabilities over 3 years: stood at $129.9 million in 2018, then changed by 0.0% to $129.9 million in 2019, then changed by 0.0% to $129.9 million in 2020.
• Business Quant data shows CMPX's Preferred Stock Liabilities at $129.9 million in Q1 2020, $129.9 million in Q4 2019, and $129.9 million in Q3 2019.